A retrospective study assessing the degree of weight change in patients with IBD treated with TNF-alpha inhibitors, vedolizumab, or ustekinumab.
Latest Information Update: 20 Dec 2021
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 20 Dec 2021 New trial record
- 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021